Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance (Q34730669)

4 August 2017

1 reference

title

Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance (English)

1 reference

4 August 2017

1 reference

1

Joseph L Kuti

1 reference

4 August 2017

3

David P Nicolau

1 reference

4 August 2017

Blair Capitano

2

1 reference

4 August 2017

1 January 2002

1 reference

4 August 2017

1 reference

4 August 2017

20

1 reference

4 August 2017

8

1 reference

4 August 2017

513-528

1 reference

https://scigraph.springernature.com/pub.10.2165/00019053-200220080-00002

4 August 2017

0 references

cites work

The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection

1 reference

12 December 2020

Consequences of intravascular catheter sepsis

1 reference

12 December 2020

Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia

1 reference

12 December 2020

Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America

1 reference

12 December 2020

Macrolide-resistant Streptococcus pneumoniae in Canada during 1998-1999: prevalence of mef(A) and erm(B) and susceptibilities to ketolides

1 reference

12 December 2020

Cost effectiveness of once-daily oral antimicrobial therapy

1 reference

12 December 2020

Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae

1 reference

12 December 2020

Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin

1 reference

12 December 2020

Effects of a pneumonia clinical pathway on time to antibiotic treatment, length of stay, and mortality

1 reference

12 December 2020

Identification of low-risk hospitalized patients with pneumonia. Implications for early conversion to oral antimicrobial therapy

1 reference

12 December 2020

Pharmacodynamic factors of antibiotic efficacy

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract

1 reference

12 December 2020

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

1 reference

12 December 2020

The clinical benefit of in-hospital observation in 'low-risk' pneumonia patients after conversion from parenteral to oral antimicrobial therapy

1 reference

12 December 2020

Trends in infectious diseases mortality in the United States.

1 reference

12 December 2020

Economic impact of streamlining antibiotic administration

1 reference

12 December 2020

Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection

1 reference

12 December 2020

Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group

1 reference

12 December 2020

Is an observation period necessary after intravenous antibiotics are changed to oral administration?

1 reference

12 December 2020

Cost-effectiveness comparison of sequential ofloxacin versus standard switch therapy

1 reference

12 December 2020

Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group

1 reference

12 December 2020

Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines.

1 reference

12 December 2020

Community-acquired pneumonia

1 reference

12 December 2020

Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999--2000, including a comparison of resistance rates since 1994--1995.

1 reference

12 December 2020

In vitro characterization of fluoroquinolone concentration/MIC antimicrobial activity and resistance while simulating clinical pharmacokinetics of levofloxacin, ofloxacin, or ciprofloxacin against Streptococcus pneumoniae.

1 reference

12 December 2020

Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections

1 reference

12 December 2020

Antibiotic Streamlining From Combination Therapy to Monotherapy Utilizing an Interdisciplinary Approach

1 reference

12 December 2020

Cost of oral antibiotic therapy

1 reference

12 December 2020

A pharmacist-initiated program of intravenous to oral antibiotic conversion

1 reference

12 December 2020

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

1 reference

12 December 2020

Early switch from intravenous to oral antibiotics in hospitalized patients with infections: a 6-month prospective study

1 reference

12 December 2020

Antimicrobial Resistance in Streptococcus pneumoniae: An Overview

1 reference

12 December 2020

Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States

1 reference

12 December 2020

Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections

1 reference

12 December 2020

Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997)

1 reference

12 December 2020

A randomized, prospective study measuring outcomes after antibiotic therapy intervention by a multidisciplinary consult team

1 reference

12 December 2020

Workplace costs associated with acute exacerbation of chronic bronchitis: a comparison of moxifloxacin and levofloxacin

1 reference

12 December 2020

Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration

1 reference

12 December 2020

Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis

1 reference

12 December 2020

Early Switch From Intravenous to Oral Antibiotics and Early Hospital Discharge

1 reference

12 December 2020

A prospective randomized study of inpatient iv. antibiotics for community-acquired pneumonia. The optimal duration of therapy

1 reference

12 December 2020

Early switch from intravenous to oral antibiotics: guidelines and implementation in a large teaching hospital.

1 reference

12 December 2020

Antibiotic kinetic and dynamic attributes for community-acquired respiratory tract infections

1 reference

12 December 2020

Pharmacodynamics and pharmacokinetics of levofloxacin

1 reference

12 December 2020

Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

1 reference

12 December 2020

Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group

1 reference

12 December 2020

Role of Antimicrobial Pharmacokinetics and Pharmacodynamics in Surgical Prophylaxis

1 reference

12 December 2020

Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.

1 reference

12 December 2020

The cost of treating community-acquired pneumonia.

1 reference

12 December 2020

Pharmacoeconomics of antimicrobial therapy

1 reference

12 December 2020

A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin

1 reference

12 December 2020

A prediction rule to identify low-risk patients with community-acquired pneumonia

1 reference

12 December 2020

Using pharmacodynamic and pharmacokinetic surrogate markers in clinical practice: optimizing antimicrobial therapy in respiratory-tract infections

1 reference

12 December 2020

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

1 reference

12 December 2020

Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections.

1 reference

12 December 2020

10.2165/00019053-200220080-00002

Identifiers

DOI

1 reference

PubMed ID

12109917

Dimensions Publication ID

4 August 2017

0 references

1 reference

PubMed ID

12109917